Drug Trial Radar · NCT05744921
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Mar 7, 2023
Primary completion
Oct 10, 2028
Study completion Oct 10, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as "study drugs" in this section. This study is looking at several other research questions, including: * How effective is the pozelimab + cemdisiran combination? * What side effects may happen from taking the study drugs? * How much of each study drug is in the blood at different times? * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
PozelimabDrug
Administered per the protocol
CemdisiranDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent serious adverse events (SAEs)Time frame: Up to week 108
- Severity of treatment-emergent SAEsTime frame: Up to week 108
- Incidence of treatment emergent adverse events of special interest (AESIs)Time frame: Up to week 108
- Severity of treatment emergent AESIsTime frame: Up to week 108
- Incidence of adverse events (AEs) leading to permanent treatment discontinuationTime frame: Up to week 108
- Severity of adverse events (AEs) leading to permanent treatment discontinuationTime frame: Up to week 108
- Percent change from baseline in lactate dehydrogenase (LDH)Time frame: Baseline to week 36
Locations
50 sites in 21 countries. Site status is shown where the registry gives one.
A Beneficencia Portuguesa de Sao Paulo, BP Mirante
São Paulo, Brazil · Recruiting
Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner
Curitiba, Jardim Santo Andre, Brazil · Recruiting
Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Hospital Pablo Tobon Uribe
Medellín, Antioquia, Colombia · Recruiting
Semmelweis University/Semmelweis Egyetem
Budapest, Hungary · Recruiting
Postgraduate Institute of Medical Education & Research
Chandigarh, India · Recruiting
Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC)
Jaipur, India · Recruiting
Amrita Institute of Medical Sciences (AIMS) and Research Centre Aims
Kochi, Kerala, India · Recruiting
K J Somaiya Super Specialty Hospital & Research Centre
Mumbai, Maharashtra, India · Recruiting
Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus
New Delhi, National Capital Territory of Delhi, India · Recruiting
SC Hematology, AOU Città della Salute e della Scienza di Torino
Torino, Italy · Recruiting
Aou Careggi
Florence, Firenze, Italy · Recruiting
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan · Withdrawn
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan · Recruiting
Jordan University Hospital (JUH)
Amman, Jordan · Recruiting
Hospital Tg Ampuan Afzan
Kuantan, Pahang, Malaysia · Recruiting
Hospital Queen Elizabeth
Kota Kinabalu, Sabah, Malaysia · Recruiting
Hospital Ampang
Ampang, Selangor, Malaysia · Recruiting
Servicio de Hematologia del Hospital Universitario de la UANL
Monterrey, Nuevo León, Mexico · Recruiting
Clinica San Felipe
Lima, Peru · Recruiting
St Lukes Medical Center
Quezon City, National Capital Region, Philippines · Recruiting
Szpital Uniwersytecki Nr2 Bydgoszcz
Bydgoszcz, Poland · Completed
In-Vivo Sp. z o.o.
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
University Clinical Center Medical University of Gdansk
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Prof Dr Ion Chiricuta Cancer Institute
Cluj-Napoca, Cluj, Romania · Recruiting
National University Hospital
Singapore, Singapore · Recruiting
Pusan National University Hospital
Busan, South Korea · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Ewha Womans University Mokdong Hospital
Seoul, South Korea · Recruiting
St. Vincent Hospital
Suwon, Gyeonggi-do, South Korea · Recruiting
Ajou University Medical Center
Suwon, Gyeonggi-do, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, Namdong-Gu, South Korea · Recruiting
Hospital Clinic de Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Basurto
Bilbao, Vizcaya, Spain · Recruiting
Changhua Christian Hospital
Changhua, Taiwan · Recruiting
Hualien Tzu Chi Hospital
Hualien City, Taiwan · Recruiting
Taichung Veterans General Hospital (VGHTC)
Taichung, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.